Facial pain treated with carbamazepin (Tegretol).
D000328:Adult; D000367:Age Factors; D000368:Aged; D002220:Carbamazepine / Q000008:administration & dosage / Q000009:adverse effects; D002986:Clinical Trials as Topic; D003984:Dibenzazepines / Q000008:administration & dosage* / Q000009:adverse effects; D005076:Exanthema / Q000139:chemically induced; D005156:Facial Neuralgia / Q000188:drug therapy*; D005260:Female; D007839:Functional Laterality; D006261:Headache / Q000139:chemically induced; D006801:Humans; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010292:Paresthesia / Q000139:chemically induced; D010919:Placebos; D012737:Sex Factors; D013997:Time Factors; D014277:Trigeminal Neuralgia / Q000188:drug therapy* / Q000503:physiopathology; D014717:Vertigo / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
D003984:Dibenzazepines; D010919:Placebos; D002220:Carbamazepine